Subscribe To

Price Alert Latest News Economic Calendar News

MESO / Mesoblast's (MESO) GVHD Drug BLA Gets FDA Priority Tag, Stock Up

Mesoblast (MESO) announces the FDA acceptance for review of the resubmitted biological license application for remestemcel-L for the treatment of children under 12 with steroid-refractory acute graft versus host disease. Stock gains on Wednesday, following the news. Read More

Demo Live Account See Partner Details

Content Topics

Mesoblast

MESO

Gvhd

Drug

Gets

Priority

Stock

Mesoblast s

meso

Posted: Mar 9 2023, 08:24

Author Name: Zacks Investment Research

MESO News

By Seeking Alpha
August 30, 2023

Mesoblast Limited (MESO) Q4 2023 Earnings Call Transcript

Mesoblast Limited (NASDAQ:MESO ) Q4 2023 Results Conference Call August 30, 2023 6:30 PM ET Company Participants Dr. Silviu Itescu - Chief Executive O

By The Motley Fool
August 7, 2023

Why Shares of Mesoblast Are Down Monday

Several analysts have recently downgraded their positions on the pharmaceutical stock. Mesoblast focuses on therapies derived from the cells of the bo

By The Motley Fool
August 4, 2023

Why Shares of Mesoblast Are Plunging Friday

Mesoblast focuses on therapies to treat autoimmune disorders. The company's resubmission of Ryoncil was given a Complete Response Letter by the FDA.

By Reuters
August 3, 2023

FDA rejects Mesoblast's cell therapy for bone marrow transplant complications

The U.S. Food and Drug Administration had rejected Mesoblast's , cell therapy for children under 12 years of age for treating a type of complication t

By Zacks Investment Research
June 23, 2023

Are You Looking for a Top Momentum Pick? Why Mesoblast Limited (MESO) is a Great Choice

Does Mesoblast Limited (MESO) have what it takes to be a top stock pick for momentum investors? Let's find out.

By Seeking Alpha
May 25, 2023

Mesoblast Limited (MESO) Q3 2023 Earnings Call Transcript

Mesoblast Limited (NASDAQ:MESO ) Q3 2023 Earnings Conference Call May 25, 2023 6:30 PM ET Company Participants Silviu Itescu – Chief Executive Offic

By Zacks Investment Research
March 9, 2023

Mesoblast's (MESO) GVHD Drug BLA Gets FDA Priority Tag, Stock Up

Mesoblast (MESO) announces the FDA acceptance for review of the resubmitted biological license application for remestemcel-L for the treatment of chil

By Seeking Alpha
March 2, 2023

Mesoblast Limited. (MESO) Q2 2023 Earnings Call Transcript

Mesoblast Limited. (NASDAQ:MESO ) Q2 2023 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Silviu Itescu – Chief Executive

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.